77 related articles for article (PubMed ID: 18826102)
1. [Proteasome inhibitor bortezomib sensitizes Hep-2 human laryngeal squamous cell carcinoma cells to ionizing radiation in vitro and in vivo].
Wang QW; Liu H; Liang YM; Wang T; Zhu XD
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Jun; 43(6):456-9. PubMed ID: 18826102
[TBL] [Abstract][Full Text] [Related]
2. Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
Kamer S; Ren Q; Dicker AP
Arch Gynecol Obstet; 2009 Jan; 279(1):41-6. PubMed ID: 18461345
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitizing properties of bortezomib depend on therapeutic schedule.
Labussière M; Pinel S; Vandamme M; Plénat F; Chastagner P
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):892-900. PubMed ID: 21168283
[TBL] [Abstract][Full Text] [Related]
4. STAT3 blockade with shRNA enhances radiosensitivity in Hep-2 human laryngeal squamous carcinoma cells.
Li X; Wang H; Lu X; Di B
Oncol Rep; 2010 Feb; 23(2):345-53. PubMed ID: 20043094
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium.
Yang X
Biomed Pharmacother; 2012 Dec; 66(8):607-11. PubMed ID: 23089480
[TBL] [Abstract][Full Text] [Related]
6. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor PS-341 in cancer therapy.
Teicher BA; Ara G; Herbst R; Palombella VJ; Adams J
Clin Cancer Res; 1999 Sep; 5(9):2638-45. PubMed ID: 10499643
[TBL] [Abstract][Full Text] [Related]
8. [hTERT promoter enhances the radiosensitivity to gene-radiation therapy of human laryngeal carcinoma transplanted in nude mice].
Huang CH; Liao ZK; Zhou FX; Wang WF; Xie CH; Zhang HY; Sun WJ; Zhou YF
Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):733-6. PubMed ID: 19173799
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
[TBL] [Abstract][Full Text] [Related]
10. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
11. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
O'Connor OA; Smith EA; Toner LE; Teruya-Feldstein J; Frankel S; Rolfe M; Wei X; Liu S; Marcucci G; Chan KK; Chanan-Khan A
Clin Cancer Res; 2006 May; 12(9):2902-11. PubMed ID: 16675587
[TBL] [Abstract][Full Text] [Related]
12. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
14. Treatment of human respiratory syncytial virus infected Balb/C mice with the proteasome inhibitor bortezomib (Velcade, PS-341) results in increased inflammation and mortality.
Lupfer C; Patton KM; Pastey MK
Toxicology; 2010 Jan; 268(1-2):25-30. PubMed ID: 19931343
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
[TBL] [Abstract][Full Text] [Related]
16. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
[TBL] [Abstract][Full Text] [Related]
17. Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines.
Wagenblast J; Hambek M; Baghi M; Knecht R
Anticancer Res; 2008; 28(2A):687-92. PubMed ID: 18507008
[TBL] [Abstract][Full Text] [Related]
18. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.
Marchi E; Paoluzzi L; Scotto L; Seshan VE; Zain JM; Zinzani PL; O'Connor OA
Clin Cancer Res; 2010 Jul; 16(14):3648-58. PubMed ID: 20501616
[TBL] [Abstract][Full Text] [Related]
19. [Radiomodifying effect of methandrostenolone on laryngeal cancer cells].
Bordiushkov IuN; Kucherova TI; Kisliakova ND; Vagner VP; Zubkova TV
Eksp Onkol; 1987; 9(2):57-9. PubMed ID: 3582242
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
Ko BS; Chang TC; Chen CH; Liu CC; Kuo CC; Hsu C; Shen YC; Shen TL; Golubovskaya VM; Chang CC; Shyue SK; Liou JY
Life Sci; 2010 Jan; 86(5-6):199-206. PubMed ID: 20006625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
